Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?

Intradetrusor injections of Botulinum toxin A—currently onabotulinumtoxinA—is registered as a second-line treatment to treat neurogenic detrusor overactivity (NDO). The common clinical practice is 30 × 1 mL injections in the detrusor; however, protocols remain variable and standardization is warrant...

Full description

Bibliographic Details
Main Authors: Amélie Huynh Le Maux, Bernadette Pignol, Delphine Behr-Roussel, Jean-Luc Blachon, Pierre-Etienne Chabrier, Sandrine Compagnie, Philippe Picaut, Jacques Bernabé, François Giuliano, Pierre Denys
Format: Article
Language:English
Published: MDPI AG 2015-12-01
Series:Toxins
Subjects:
abobotulinumtoxinA
injection procedure
injection site number
neurogenic detrusor overactivity
spinal-cord injury
Online Access:http://www.mdpi.com/2072-6651/7/12/4896

Similar Items

Similar Items